(...virus (AAV) to carry the new genes into a patient's body.
The viruses do not cause disease in humans)
Well it is probably smart for Berger to distance himself from Ad,
interesting that in the press release it's suddenly AAV instead
of the Wilson hybrid Ad/AAV vector. It's funny, months ago
when it was all gloom and doom on the Yahoo board, I kept
trying to express that the real story behind Ariad was not
the vector, and that the Upenn event should not have any
bearing on ARGENT--and yet I think it was a drag on ARIA, even
after the toxic was undone.
Well, not knowing what I should do, I've simply gone back to
the basics on what to own for the AAV--and TGEN's Parker has been
very clear about their angle on AAV, so I find myself parked
in that one, and going nowhere fast! Oh what I wouldn't give
to have had a pile of those warrants still when they touched
$6 today!
<any thought on is ARIA still a buy at these levels?>
Who can say--heck, FBIOX spent the last couple years
selling ARIA at lower and lower prices and now we are
talking about it being a buy in double digits--dunno,
maybe, but you don't want my advice--call the company
and see if you can get any hints as to how the hunt
for an ARGENT partner is going (having the shareprice
way up has to help, dealing with strength these days!). |
